- $29.32bn
- $28.61bn
- $606.42m
Annual cashflow statement for Insmed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -435 | -482 | -750 | -914 | -1,277 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 115 | 62.2 | 239 | 219 | 403 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -58.6 | 6.58 | -39.2 | -3.18 | -80.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -363 | -400 | -536 | -684 | -935 |
| Capital Expenditures | -7.29 | -9.88 | -13.3 | -21.9 | -32.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -57 | -24.7 | -210 | -561 | -32 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -64.3 | -34.6 | -224 | -583 | -64.6 |
| Financing Cash Flow Items | -16.8 | -18.4 | -1.22 | -3.74 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 613 | 793 | 168 | 1,341 | 954 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 184 | 357 | -592 | 72.7 | -44.6 |